Skip to main
Genetic science research
George Mason University
News

Petricoin receives funding for project examining ovarian cancer detection with blood- and imaging-based biomarkers

Elizabeth Grisham

Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for a project examining ovarian cancer detection with blood- and imaging-based biomarkers.  

For this project, CAPMM researchers will receive tissue and sera samples from their university collaborator partners. The researchers will perform reverse phase protein array (RPPA) analysis and nanoparticle‐enabled biomarker capture and high-resolution mass spectrometry analysis on these specimens. The researchers will share and jointly analyze the results. 

"This exciting project aims to discover biomarkers in the blood to detect the earliest stages of ovarian cancer—looking at the premalignant lesions in the fallopian tube. The hope would be to combine blood and tissue based testing with imaging to detect ovarian cancer at the earliest premalignant stages," Petricoin said.  

Petricoin received $160,939 from the University of Arizona on a subaward from the U.S. Department of Health and Human Services for the first year of this five-year grant that began in January 2022. Total funding for the award will be $826,000. 

* The programs and services offered by George Mason University are open to all who seek them. George Mason does not discriminate on the basis of race, color, religion, ethnic national origin (including shared ancestry and/or ethnic characteristics), sex, disability, military status (including veteran status), sexual orientation, gender identity, gender expression, age, marital status, pregnancy status, genetic information, or any other characteristic protected by law. After an initial review of its policies and practices, the university affirms its commitment to meet all federal mandates as articulated in federal law, as well as recent executive orders and federal agency directives.